Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

Cleveland Biolabs (NASDAQ: CBLI)

$3.72 USD -$0.09 (-2.36%)
Last Price $3.72
Net Change $-0.09 (-2.36%)
Bid $0
Ask Price $0
Open Price $3.83
Previous Close Price $3.81
High Price $3.87
Low Price $3.61
Number of Trades 157
Volume 62,100
Fifty Two Week High $5.55 (2017-04-19)
Fifty Two Week Low $1.22 (2016-12-29)
Average Daily Volume 873,079
Share Outstanding 11,280 Shares
Total Dividend Payout 0/yr
Dividend Yield 0%
1st Quarter Earnings $ ()
2nd Quarter Earnings $ ()
3nd Quarter Earnings $ ()
4th Quarter Earnings $ ()
PE Ratio $0
EPS Growth $0
Recent Earnings $
Annual EPS $-0.33
Last Quarter EPS $
Market Capitalization $0.04B
Insider Shareholders % 0.0244%
Annual Revenue $0B
No. Shares Outstanding 11,280
Inst. Shareholder % 1.7%
Annual Net Income $-0B
TTM Net Profit Margin $-111.28
1-Year Return 68.33%
3-Year Return -67.37%
5-Year Return -86.12%
5-Year Revenue Growth -59.95%
5-Year Earnings Growth -98.36%
5-Year Dividend Growth 0%
Annual Dividend $0
Annual Dividend Yield 0%
Change in EPS YTD %
Dividends per Share $
Stock Split Ratio 1-20
Beta 0.76
CLEVELAND BIOLABS, INC. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. The Company's proprietary technology platform is based on the ability to suppress or stimulate programmed cell death (apoptosis). CBLI's drugs can switch apoptosis on and off by affecting key regulators of cell response to stresses, such as radiation or ischemia. CBLI is pursuing three key areas of research: Biodefense for Acute Radiation Syndrome, Cancer Treatment, and Tissue Protection.

CBLI News & Stock Updates